Le Comité consultatif national sur les annexes de médicaments (CCNAM) a tenu une rencontre le 2 décembre 2024 et a proposé les recommandations provisoires suivantes (disponible qu’en anglais) :

• Cetirizine or its salts, when sold in concentrations of 8.5 mg or less of cetirizine base per unit dose, in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 119 mg of cetirizine base, remain in Schedule III

• Cetirizine or its salts, when sold in concentrations of 8.5 mg or less of cetirizine base per unit dose, in products labelled for use in children aged 2 to 11 years, in package sizes containing no more than 119 mg of cetirizine base, be granted Unscheduled status

• Cetirizine or its salts, when sold in concentrations of 8.5 mg or less of cetirizine base per unit dose, in products labelled for use in individuals 12 years of age and older, remain Unscheduled

**Note: 8.5 mg of cetirizine base is approximately equivalent to 10 mg of cetirizine hydrochloride.

L’ANORP doit recevoir toute objection à ces recommandations provisoires avant le 9 janvier 2025 en fin de journée. Veuillez envoyer toute question ou tout commentaire au secrétariat du CCNAM en écrivant à ndsac@napra.ca.